Entrada Therapeutics, Inc.
TRDA
$10.07
$0.222.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.23% | -90.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.23% | -90.51% | |||
| Cost of Revenue | 1.28% | 18.09% | |||
| Gross Profit | -2.28% | -211.97% | |||
| SG&A Expenses | -5.66% | 6.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.27% | 15.23% | |||
| Operating Income | -0.43% | -115.00% | |||
| Income Before Tax | -1.29% | -147.42% | |||
| Income Tax Expenses | 267.42% | -- | |||
| Earnings from Continuing Operations | -2.39% | -148.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.39% | -148.45% | |||
| EBIT | -0.43% | -115.00% | |||
| EBITDA | -0.01% | -119.80% | |||
| EPS Basic | -2.08% | -146.85% | |||
| Normalized Basic EPS | -0.99% | -145.83% | |||
| EPS Diluted | -2.08% | -146.85% | |||
| Normalized Diluted EPS | -0.99% | -145.83% | |||
| Average Basic Shares Outstanding | 0.30% | 0.65% | |||
| Average Diluted Shares Outstanding | 0.30% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||